Title Image

Investor Relations

Company Profile
Company Name Handa Pharmaceuticals, Inc.
Ticker Symbol Handa Pharma
Stock Code 6620
Market Emerging Stocks for Trading on the Taipei Exchange
Industry Biotechnology and Medical Care
Establishment Date 2014-05-08
Listing Date 2016-12-28
Paid-up Capital NT$ 1,155,660,000
Chairman of the Board Bill Liu, Ph.D.
General Manager Mr. Toshiyo Chen
Stock Transfer Agent Department of Stock Affairs and Transfer, Horizon Securities Co., Ltd.
Accounting Firm Deloitte & Touche
Address 3F-1&3F-2, No.23, Nanke 3rd Rd., Tainan City 74147, Taiwan (R.O.C.)
Telephone +886-6-5057508
Website http://www.handapharma.com.tw
organizational chart
Division Main Duties
Chairman of the Board  Plan and establish the overall business objectives and strategies of the company, implement board resolutions, and convene board meetings and shareholders’ meetings.
CEO Plan and coordinate various global affairs and operations between the parent company / subsidiary / second-tier subsidiary.
General Manager Formulate, plan and supervise the Company’s operational plans, objectives, and quality policies.
Internal Audit Evaluation and follow-up of the Company’s internal control system and the soundness, legitimacy, and effectiveness of its administrative systems.
B&D Division Achieving commerical performance in line with the Company’s business growth targets. Client development; knowing clients’ needs and providing solutions.
R&D Division Investigation of potential R&D targets and development into new products  with commercial value.Execution of new-product and new-dosage-form projects, including clinical trials, bioavailability tests, and bioequivalence tests.
Regulation Division Review of drug inspection/registration documents to ensure validity and approval. Provision of legal information relevant to drug inspections/registration.
General Administration Division Planning and handling of the Company’s cash and fundingmanagement; handling of the Company’s accounting operations and the compilation of management reports for the management team as references to strategize.
Planning and execution of operations related to tax affairs.

Founder/Chairman/Chief Executive Officer

Bill Liu, Ph.D.

With over 20 years of experience, Dr. Liu is an accomplished executive and scientist with a proven track record of building effective teams, technology-based product portfolios and successful pharmaceutical businesses.
Dr. Liu founded Handa Pharmaceuticals in November 2005. Prior to founding Handa, he served as Chief Operating Officer and Vice President of Product Development and Operations at Anchen Pharmaceuticals from September 2002 to August 2005. As its first employee, Dr. Liu helped to set up Anchen’s business operations including formulation development, analytical services, quality assurance, information technology, regulatory affairs and a cGMP facility. Under his direction, the team successfully developed a pipeline of Paragraph IV controlled-release generic products, two of which were first-to-file.
Prior to joining Anchen, Dr. Liu served in various management positions in product development and business development at Yamanouchi Pharma Technologies, where he developed and commercialized Benadryl® FastMelt Orally Disintegrating Tablets, among other proprietary products. From 1992 to 1997, Dr. Liu was employed by Impax Pharmaceuticals, Watson Pharmaceuticals, and Southern Research Institute, where he was credited with the development of several generic controlled-release products.

Dr. Liu received a B.S. degree in Pharmacy from China Pharmaceutical University in 1983 and a Ph.D. degree in Industrial and Physical Pharmacy from Purdue University in 1992.

Director/General Manager

Toshiyo Chen

Mr. Chen, with over 20 years of corporate management experience, specializes in the management, corporate governance, negotiation, marketing and value addition & commercialization of biotech products.

With a bachelor degree in pharmacy from Kaohsiung Medical College and EMBA from National Taiwan University, Mr. Chen has abundant industrial experience, with as chairman of Pharmira Laboratory Company Ltd., general Manager of TSH Biopharm Corporation Ltd., and sales director/senior director of TTY Biopharm Company Limited.

Chief Technology Officer

KC Sung, Ph.D.

Cofounder of Pharmira Laboratory Company Ltd., Dr. Sung specializes in controlled release formulation, biopharmacy, physical pharmaceutics and industrial pharmacy. He has abundant experience in the development of several generic drugs approved by TFDA, and assisted in the development of generic drugs approved by FDA.

With a bachelor degree in pharmacy from National Taiwan University and a doctorate degree in pharmaceutical chemistry from University of Kansas, Dr. Sung served as adjunct professor in clinical pharmacy and pharmaceutical sciences of National Cheng Kung University, professor of the department of pharmacy & institute director of the graduate institute of pharmaceutical science in Chia Nan University, and consultant of severl pharmaceutical companies & TFDA.

Director/Senior Vice President – Quality Affairs

Maggie Chang, Ph.D.

Dr. Chang has over 20 years of experience in quality assurance and quality control, Good Laboratory Practices and Good Manufacturing Practices compliance and oversight, analytical methods development, regulatory submissions, and management of clinical production and testing.

Prior to joining Handa, Dr. Chang served as Vice President of Quality Affairs at Anchen Pharmaceuticals. While at Anchen, she worked on numerous development projects which resulted in ANDA regulatory submissions, including the company’s first ANDA, which received FDA approval in November 2005. From 1996 to 2002, Dr. Chang held various management positions in the R&D Analytical Department at Impax Laboratories. She possesses extensive experience in quality issues associated with laboratory and material management, including controlled substances. Dr. Chang received a B.S. degree in Pharmacy from National Taiwan University in 1989 and a Ph.D. degree in Industrial and Physical Pharmacy from Purdue University in 1996.

Senior Vice President – Business Development

Stephen D. Cary, M.B.A.

Mr. Cary has over 20 years of sales, marketing, and business development experience in branded and generic pharmaceutical products and medical devices. Prior to joining Handa, he served as Executive Vice President of Business Development and Co-founder of Cary Pharmaceuticals Inc., a specialty pharmaceutical company based in the Washington, DC area. From 1992-1999, Mr. Cary held various sales and marketing roles at Glaxo Inc. (now GlaxoSmithKline) and was involved in the product launches and line extensions of several key growth products (Ceftin®, Imitrex®, Serevent®, Zantac®, Zofran®, and Zyban®) for the hospital and retail markets, across multiple therapeutic areas including addiction medicine, anti-infectives, CNS, gastrointestinal, and respiratory.

Mr. Cary received a B.B.A. degree in Marketing from the University of Iowa in 1992 and an M.B.A. degree in Management and Entrepreneurship from the University of Maryland in 1999.

Vice President – Regulation

John Duan, Ph.D.

Joining Handa Pharma in 2016, Dr. Duan received a Ph.D. degree in pharmacy from Louisiana State University and served as head of center for drug evaluation and research of US FDA previously.

Dr. Duan has abundant experience and knowledge in the submissions and regulatory activities. He now leads Handa’s regulatory aspects including pre-market regulatory path planning.

Chief Financial Officer

Stephen Chen

With over 20 years of financial management experience, Mr. Chen specializes in financial management, capital market and financial planning. His professional knowledge and experience could further enhance Handa’s business strategy and execution.

With a master’s degree in finance from the City University of New York, Mr. Chen boasts abundant industrial experience, with as CFO of the Aten International Co., Ltd. and E INK Holdings Inc. His cross-border financial management experience is conducive to him helping the company formulate strategy and cut corporate risk.

Auditing Director

Jessica Shih

With years of auditing experience, Ms. Shih specializes in helping enterprises with IPO, establishment of internal-control system, auditing, and taxation inspection.

With a MBA from University of Illinois, Ms. Shih served as internal auditing officer and accounting officer at PlexBio Co.,Ltd. and YB Biotech.

Financial Director

Emi Yang

With over 15 years of experience in accounting, Ms. Yang specializes in the establishment and improvement of accounting flow and taxation planning. Her abundant experience in cross-border accounting and taxation affairs, is conducive to her helping the company enhance the efficiency of financial/accounting flow.

With a master degree in accounting from the George Washington University, Ms. Yang has accountant licenses in Virginia of USA and ROC.